Overview
After multiple successful roadshow events across three states, the Skin Health Institute is proud to once again partner with Bristol Myers Squibb and the Australasian Dermatology Registry to bring you an exclusive roadshow event in Perth.
The agenda for the evening will see A/Prof Peter Foley delve into the fascinating world of advanced targeted therapies and how they align with the cutting-edge psoriasis treatment goals of 2023.
Following that, A/Prof Kurt Gebauer, will share his involvement with the Australasian Dermatology Registry, with a particular focus on his role in the Psoriasis Scientific Advisory Committee.
A/Prof Peter Foley will then return to the stage to discuss the benefits of the new Registry and the opportunity it offers to accumulate CPD category 3 points.
Limited spots are available!
AGENDA
6:30pm | Arrival and registration |
6:45pm | Advanced targeted therapies in the context of new psoriasis treatment goals |
7:20pm | Australasian Psoriasis Registry Reimagined |
8:30pm | Meeting close |
Speaker
MBBS FACD FACP
A/Prof Kurt Gebauer is a dermatologist, Director of
Fremantle Dermatology and Senior Lecturer at the
University of Western Australia. He completed a
Bachelor of Medicine and a Bachelor of Surgery from
the University of Western Australia in 1985 and was
awarded a Fellowship of the Australasian College of
Dermatologists in 1992. He undertook post-graduate
training in the United Kingdom, including research in industrial dermatitis. For his academic interests, he was awarded a Clinical Associate Professorship from the University of Western Australia in 2008.
A/Prof Gebauer is an International Fellow of the American Academy of Dermatology and International Dermatology Society. He has numerous research interests, particularly in evaluating and developing innovative pharmaceutical agents used to treat dermatological conditions. He has contributed to over 40 clinical trials, authored over 40 journal articles and is an invited international guest speaker at various meetings and conventions.